Selexipag

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 336 publications

Selexipag for Pulmonary Hypertension, TAVI and more.

Selexipag for Pulmonary Hypertension, TAVI and more.

Journal: Anatolian journal of cardiology

Published: April 01, 2026

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study".

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study".

Journal: Anatolian journal of cardiology

Published: March 17, 2026

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Journal: Cureus

Published: March 09, 2026

Corrigendum to "Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)" [Vascular Pharmacology 162 (2026) 107585].

Corrigendum to "Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)" [Vascular Pharmacology 162 (2026) 107585].

Journal: Vascular pharmacology

Published: February 26, 2026

Treatment of Pulmonary Arterial Hypertension in Lithuania: Current Situation and Analysis of Survival of Patients Treated with Different Treatment Regimens.

Treatment of Pulmonary Arterial Hypertension in Lithuania: Current Situation and Analysis of Survival of Patients Treated with Different Treatment Regimens.

Journal: Journal of clinical medicine

Published: February 26, 2026

Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Journal: Cureus

Published: February 19, 2026

Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Cardiology in review

Published: February 18, 2026

A treprostinil inhaler (Yutrepia) for pulmonary hypertension.

A treprostinil inhaler (Yutrepia) for pulmonary hypertension.

Journal: The Medical letter on drugs and therapeutics

Published: February 06, 2026

Interpretive considerations on real-world use of selexipag and parenteral prostacyclin in pulmonary arterial hypertension.

Interpretive considerations on real-world use of selexipag and parenteral prostacyclin in pulmonary arterial hypertension.

Journal: Journal of cardiology

Published: February 03, 2026

Comment on: Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study: Reply.

Comment on: Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study: Reply.

Journal: Rheumatology (Oxford, England)

Published: January 28, 2026

Editorial: 10-year data on oral selexipag: Long-term survival, safety, and dosing insights in pulmonary arterial hypertension from the GRIPHON study and its open-label extension-big data-small impact.

Editorial: 10-year data on oral selexipag: Long-term survival, safety, and dosing insights in pulmonary arterial hypertension from the GRIPHON study and its open-label extension-big data-small impact.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: January 24, 2026

Comment on: Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study.

Comment on: Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study.

Journal: Rheumatology (Oxford, England)

Published: January 14, 2026

Showing 1-12 of 336

Last Updated: 04/28/2026